FDA Clearance of Investigational New Drug for Patients with Krabbe Disease

January 4, 2021 by Dan Salvo Forge Biologics has received IND, IBC, and IRB clearance for FBX-101, a gene therapy for patients with Krabbe disease, a rare and fatal genetic disorder FBX-101 is a first-in-human potential treatment utilizing an adeno-associated virus (AAV) to deliver a functioning copy of the GALC gene to cells in the CNS and …

FDA Clearance of Investigational New Drug for Patients with Krabbe Disease Read More »